Design

• A retrospective cohort study using data from patients with obesity/morbid obesity and AF enrolled in the Veterans Health Administration system and patients who initiated apixaban, rivaroxaban, dabigatran, or warfarin (Jan 1, 2010
  to Dec 31, 2018)

Outcomes

• Ischemic stroke, any major bleeding, GI bleeding, ICH, acute myocardial infarction, heart failure, and all-cause
  mortality

Included

• Patients with obesity (≥120 kg) who initiated apixaban, dabigatran, rivaroxaban or warfarin between 2013 and 2018
• The secondary analysis included patients with a BMI >40 kg/m²
• Diagnosis of AF (ICD-9-CM code 427.31 or ICD-10-CM codes I48.0, I48.1, I48.2, and I48.91) prior to initiation of
  DOAC or warfarin

Excluded

• Patients initiating edoxaban